AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein MCM10 homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7L590

UPID:

MCM10_HUMAN

Alternative names:

-

Alternative UPACC:

Q7L590; A8K9I6; B7ZKZ8; Q3MIR3; Q7LD55; Q96GX4; Q96NB6; Q9H0D7; Q9H3P9; Q9P177

Background:

Protein MCM10 homolog plays a pivotal role in DNA replication, acting as a bridge between the MCM2-7 helicase and the DNA polymerase alpha/primase complex. It ensures the initiation of DNA replication and safeguards against DNA damage during this critical process. MCM10's involvement in the RBBP6 and ZBTB38-mediated regulation of DNA replication and stability of common fragile sites further underscores its essential function in maintaining genomic integrity.

Therapeutic significance:

Linked to Immunodeficiency 80 with or without congenital cardiomyopathy, Protein MCM10 homolog's genetic variants highlight its clinical relevance. Understanding its role could pave the way for innovative therapeutic strategies targeting the underlying genetic mechanisms of this immunologic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.